Gastroenterology

In a poster presented at ERS, researchers find the complement and coagulation cascades pathway was up-regulated in response to airway presence of Moraxella genera that might suggest an activation of systemic innate immunity in response to Moraxella.

There was no differences found between liver transplant patients and a control group on the proportion of hospitalized patients and patients who required intensive care.

No life-threatening adverse events occurred in the 150 patient trial to treat non-alcoholic fatty liver disease.

A sibling control group showed similar results as a general population control group.

A gastroenterologist discusses how gastrointestinal symptoms are manifesting in patients with COVID-19.

Dr. Erica Brenner talks about how gastroenterologists should safely return to screening and diagnosing patients.

An expert discusses how a registry of gastrointestinal symptoms is leading research during COVID-19.

A gastroenterologist discusses some of the findings regarding COVID-19 and gastrointestinal symptoms.

Firmicutes bacteria can help produce metabolites that maintain intestinal barriers and mucosal immunity.

There is a higher prevalence of IBS found in women than men.

Nearly two-thirds of COVID-19 patients have gastrointestinal symptoms.

The expansion makes history for the injection biologic.

The association of DAA treatment with mortality did not differ by sex in the cirrhosis group.

New scoring model is based on an eight-point threshold to accurately predict patients at a low risk of adverse outcomes.

The 8-7 decision allows Mallinckrodt to move forward with a Sept. 12 PDUFA date for the investigational agent.

Patients in the multidisciplinary-care group were more likely to experience a 50% or higher reduction in all Gastrointestinal Symptom Severity Index symptom clusters than the patients who were in the standard-care group.

In a sample of patients treated with laparoscopic ileocecal resection, 42% (n = 29) of patients did not require additional Crohn’s disease-related medication, while 48% (n = 14) were given prophylactic immunomodulator therapy.

The diversity of the fecal mycobiome of the last sample collected was 2.5-fold higher in COVID-19 patients than it was in the control group.

Ozanimod could soon be added to the ever growing stable of potential treatments for Crohn’s disease.

The FDA recommends additional safety and efficacy data from the ongoing REGENERATE trial.

Prior family exposure represented the factor with the second highest IRR behind hospital exposure.

The median 12-month risk of clinical relapse in patients with MES 1 was 28.7%, while the estimated annual risk of clinical relapse in patients with a MES 0 was 13.7%.

During the induction period, patients in the treatment group had higher incidences of infections and serious infectious compared to placebo.

A recent analysis is examining potential factors associated with adverse gastrointestinal events in patients using semaglutide and whether it mitigates benefit.

Between 2002-2019, NASH is the leading liver indication for women without HCC.